Bio Medica LaboratoriesNSE:BMLL +0.49%14 PB Ratio is 12.30 as of Jun. 29, 2026, which is 7% above its 10-year median of 11.48. GuruFocus rates NSE:BMLL with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 786 Medical Devices & Instruments companies, Bio Medica Laboratories ranks worse than 93.38% on this metric.
The historical rank and industry rank for Bio Medica Laboratories's PB Ratio or its related term are showing as below:
NSE:BMLL'
s PB Ratio Range Over the Past 10 Years
Min: 9.88 Med: 11.48 Max: 12.3
Current: 12.3
During the past 3 years, Bio Medica Laboratories's highest PB Ratio was 12.30. The lowest was 9.88. And the median was 11.48.
NSE:BMLL's PB Ratio is ranked worse than 93.38% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 2.015
vs NSE:BMLL: 12.30
During the past 12 months, Bio Medica Laboratories's average Book Value Per Share Growth Rate was 198.30% per year.
Back to Basics: PB Ratio
Bio Medica Laboratories (NSE:BMLL) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Medica Laboratories PB Ratio Chart
Bio Medica Laboratories Annual Data
Trend
Mar23
Mar24
Mar25
PB Ratio
0.00
0.00
0.00
Bio Medica Laboratories Semi-Annual Data
Mar23
Mar24
Mar25
PB Ratio
0.00
0.00
0.00
NSE:BMLL vs ISRG, BDX, MDLN: PB Ratio Comparison
For the Medical Instruments & Supplies subindustry, Bio Medica Laboratories's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Medica Laboratories PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio Medica Laboratories's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bio Medica Laboratories's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Bio Medica Laboratories (NSE:BMLL) has a PB Ratio of 12.30 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bio Medica Laboratories and its competitors. This is near median its historical median of 11.48. Over the past decade, Bio Medica Laboratories' PB Ratio has ranged from 9.88 to 12.30. According to the industry distribution chart, Bio Medica Laboratories ranks #734 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 93.4%.
Is Bio Medica Laboratories' PB Ratio too high?
Bio Medica Laboratories' current PB Ratio of 12.30 is near median its 10-year median of 11.48. Over the past 10 years, this metric has ranged from a low of 9.88 to a high of 12.30. The Medical Devices & Instruments industry median PB Ratio is 2.02. Bio Medica Laboratories' value of 12.30 is 510.4% above this industry median. Based on the distribution chart, Bio Medica Laboratories ranks #734 out of 786 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bio Medica Laboratories has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Bio Medica Laboratories' PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bio Medica Laboratories ranks #734 out of 786 companies for PB Ratio. This places Bio Medica Laboratories in the lower half of its industry. The industry median PB Ratio is 2.02. Bio Medica Laboratories' value of 12.30 is 510.4% above this benchmark. Historically, Bio Medica Laboratories' own PB Ratio has ranged from 9.88 to 12.30 over the past decade. While the company's 10-year median is 11.48 vs. the industry median of 2.02, Bio Medica Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.02, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio Medica Laboratories's current PB Ratio of 12.30 is 510.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bio Medica Laboratories and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Medica Laboratories's current PB Ratio is 12.30, which is near median its own 10-year median of 11.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Medica Laboratories stock overvalued right now?
Bio Medica Laboratories (NSE:BMLL) has a current PB Ratio of 12.30. The current PB Ratio is 12.30, which is near median its 10-year median of 11.48 and 510.4% above the Medical Devices & Instruments industry median of 2.02. Bio Medica Laboratories' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Bio Medica Laboratories (NSE:BMLL), the current PB Ratio is 12.30 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Medica Laboratories Ltd is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The majority of revenue is derived from the sales of Liquid injections. Geographically, it operates predominantly in India, and internationally, it exports to Afghanistan.
14GF Score
Get the complete analysis for NSE:BMLL
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BMLL has been successfully added to your 